Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
{{output}}
Background: Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment acro... ...
